{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:04:44Z","timestamp":1785153884168,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euf.2026.05.024","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:31:02Z","timestamp":1785151862000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA Therapy Grey Zones: Actinium, Lutetium, or Terbium for the Future of Radioligand therapy?"],"prefix":"10.1016","author":[{"given":"Valentino","family":"Dragonetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-7315","authenticated-orcid":false,"given":"Francesco","family":"Mattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.05.024_b0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.05.024_b0010","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1021\/cr500171e","article-title":"Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications","volume":"115","author":"Banerjee","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.euf.2026.05.024_b0015","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O\u2019Donoghue","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.024_b0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.euf.2026.05.024_b0025","article-title":"Genomic correlates of prostate-specific membrane antigen expression and response to 177LuLu-PSMA-617: a retrospective multicenter cohort study","volume":"8","author":"Raychaudhuri","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.euf.2026.05.024_b0030","doi-asserted-by":"crossref","first-page":"S1216","DOI":"10.1016\/j.annonc.2025.08.3007","article-title":"2391P LuPARP: phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)","volume":"36","author":"Sandhu","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2026.05.024_b0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1470-2045(26)00017-3","article-title":"[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b\/2 study","volume":"27","author":"Sandhu","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.024_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Front Med"},{"issue":"7","key":"10.1016\/j.euf.2026.05.024_b0045","doi-asserted-by":"crossref","first-page":"CT224","DOI":"10.1158\/1538-7445.AM2024-CT224","article-title":"Abstract CT224: Preliminary efficacy and safety results from the TATCIST trial: PSMA-directed targeted alpha therapy with FPI-2265 ([225Ac]Ac-PSMA-I&T) in mCRPC","volume":"84","author":"Delpassand","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.euf.2026.05.024_b0050","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.024_b0055","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.024_b0060","doi-asserted-by":"crossref","unstructured":"Saad F, Hotte SJ, Jayaram A, et al. First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in metastatic castration-resistant prostate cancer: dose-escalation results of the phase 1 PAnTHa study. Presented at: ASCO Genitourinary Cancers Symposium; San Francisco, CA, USA; 2026. NCT06217822.","DOI":"10.1200\/JCO.2026.44.7_suppl.19"},{"key":"10.1016\/j.euf.2026.05.024_b0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225 actinium and 213 bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.euf.2026.05.024_b0070","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2026.05.024_b0075","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2026.05.024_b0080","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (Violet): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.024_b0085","doi-asserted-by":"crossref","unstructured":"Hansen AR, Tagawa ST, Sandhu S, et al. Results from the phase 1b dose escalation of [212Pb]Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer: the TheraPb trial. Presented at: ESMO Congress; Berlin, Germany; 2025. NCT05720130.","DOI":"10.1016\/j.annonc.2025.08.3004"},{"key":"10.1016\/j.euf.2026.05.024_b0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:31:05Z","timestamp":1785151865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"alternative-id":["S2405456926000957"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.024","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA Therapy Grey Zones: Actinium, Lutetium, or Terbium for the Future of Radioligand therapy?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}